Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy.

Autor: Weinstock LB; Washington University School of Medicine, St Louis, MO 63141, USA, lw@gidoctor.net, Fern SE, Duntley SP
Jazyk: angličtina
Zdroj: Digestive diseases and sciences [Dig Dis Sci] 2008 May; Vol. 53 (5), pp. 1252-6. Date of Electronic Publication: 2007 Oct 13.
DOI: 10.1007/s10620-007-0021-0
Abstrakt: Background: Small intestinal bacterial overgrowth (SIBO) occurs in irritable bowel syndrome (IBS) and fibromyalgia. Since restless legs syndrome (RLS) occurs with fibromyalgia, a link between IBS, SIBO, and RLS was studied.
Methods: BS patients with abnormal lactulose breath tests received rifaximin 1,200 mg day(-1) for 10 days, followed by tegaserod 3 mg, long-term, and 1 month of zinc 220 mg day(-1) and once-daily probiotic (N = 11) or rifaximin monotherapy (N = 2). IBS symptom improvement was assessed after rifaximin. RLS symptoms, IBS symptoms, and overall IBS global improvement were assessed at last posttreatment visit: 8/10 patients were followed long-term (mean, 139 days; range, 54-450 days).
Results: Ten of 13 patients exhibited > or =80% improvement from baseline in RLS symptoms. Five maintained complete resolution of RLS symptoms. Global gastrointestinal symptom improvement was great (n = 6), moderate (n = 5), or mild (n = 2).
Conclusion: This study suggests that SIBO associated with IBS may be a factor in some RLS patients and SIBO therapy provides long-term RLS improvement.
Databáze: MEDLINE
Externí odkaz: